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AbstrAct
Introduction Cardiovascular disease (CVD) is a major 
cause of mortality in renal transplant recipients (RTRs). 
General population risk scores for CVD underestimate 
the risk in patients with chronic kidney disease (CKD) 
suggesting additional non-traditional factors. Renal 
transplant recipients also exhibit elevated inflammation 
and impaired immune function. Exercise has a positive 
impact on these factors in patients with CKD but there is a 
lack of rigorous research in RTRs, particularly surrounding 
the feasibility and acceptability of high-intensity interval 
training (HIIT) versus moderate-intensity continuous 
training (MICT) in this population. This study aims to 
explore the feasibility of three different supervised aerobic 
exercise programmes in RTRs to guide the design of future 
large-scale efficacy studies.
Methods and analysis Renal transplant recipients will be 
randomised to HIIT A (16 min interval training with 4, 2 and 
1 min intervals at 80%–90% of peak oxygen uptake (VO
2 
peak)), HIIT B (4×4 min interval training at 80%–90% VO2peak) 
or MICT (~40 min cycling at 50%–60% VO2peak) where they 
will undertake 24 supervised sessions (approximately 
thrice weekly over 8 weeks). Assessment visits will be 
at baseline, midtraining, immediate post-training and 3 
months post-training. The study will evaluate the feasibility 
of recruitment, randomisation, retention, assessment 
procedures and the implementation of the interventions. 
A further qualitative sub-study QPACE-KD (Qualitative 
Participant Acceptability of Exercise in Kidney Disease) 
will explore patient experiences and perspectives through 
semistructured interviews and focus groups.
Ethics and dissemination All required ethical and 
regulatory approvals have been obtained. Findings will be 
disseminated through conference presentations, public 
platforms and academic publications.
trial registration number Prospectively registered; 
ISRCTN17122775.
IntroductIon
Cardiovascular disease (CVD) is a major 
cause of morbidity and mortality after kidney 
transplantation and a key factor limiting 
graft survival.1 2 Most recent data suggest 
that the proportion of mortalities in kidney 
transplant recipients attributed to CVD or 
stroke is 22%3; however, this figure does not 
emphasise the total impact on graft survival 
and quality of life of non-fatal events such as 
acute myocardial infarction, heart failure, 
stroke and cardiac arrhythmias.2 Numbers 
of transplants per year are currently rising,3 
highlighting the need for cost-effective CVD 
prevention and risk factor management 
strategies for sustained patient health, graft 
survival and reduced healthcare burden.4
Traditional models of predicting CVD risk 
underestimate the risk in patients with chronic 
kidney disease (CKD) suggesting that kidney 
disease and transplantation introduce unique 
CVD risk factors not akin to the general popu-
lation.5 Immunosuppressive medication can 
exacerbate traditional risk factors such as poor 
lipid profile, elevated blood pressure and the 
incidence of new onset diabetes.6 7 Weight 
gain, predominantly fat, is common in renal 
transplant recipients (RTRs) with 60% having 
a midarm fat area that is within the top 10% 
of values for the general population.8 Unique 
haemodynamic challenges (anaemia, hyper-
tension and volume expansion) in RTRs can 
accelerate cardiomyopathy in the absence 
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Protocol
strengths and limitations of this study
 ► This study provides a multidisciplinary approach 
with a variety of quantitative and qualitative 
outcome measures which will contribute to future 
large-scale randomised control trial design with 
focus on negative cardiovascular disease outcomes 
in renal transplant recipients (RTRs).
 ► This study addresses the urgent need to determine 
the feasibility of differing aerobic exercise types in 
RTRs to inform future advice and recommendations.
 ► This study specifically contributes to the limited 
literature on the feasibility of high-intensity interval 
training in solid organ transplant patients.
 ► As a limitation, the sample size is limited due to the 
study being centred on feasibility in preparation for 
future efficacy trials.
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of the usual observation of concurrent ischaemic heart 
disease.2 These haemodynamic stresses are a likely contrib-
utor to the paradoxically common vascular and systemic 
inflammation observed in RTRs.9 Studies have suggested 
that elevations in novel biomarkers of inflammation are 
not just indicative but also contributory to CVD develop-
ment.10 11
Empirical evidence suggests that physical activity has 
‘anti-inflammatory’ consequences.11 Recent exercise inter-
vention studies in kidney patients who have not reached 
end-stage renal disease demonstrate reduced traditional 
and novel markers of CVD risk and improved physical func-
tion.12–14 Similarly, dialysis patients have shown lowered 
markers of systemic inflammation15 and improvements in 
arterial stiffness.16 However, given its probable benefits, 
there is a shortfall in literature surrounding the role of 
physical activity in the management of CVD risk in RTRs.17 
With a precarious balance of immune function and non-tra-
ditional CVD risk factors, current exercise guidelines may 
not be appropriate for this population.
Moderate-intensity continuous training (MICT) such as 
30–40 min brisk walking on 3 days of the week12 or intradi-
alytic cycling15 have been used and shown to be beneficial 
in reducing markers of CVD risk in patients with kidney 
disease. There has been a recent abundance of literature 
surrounding high-intensity aerobic protocols, particularly 
high-intensity interval training (HIIT) which suggests a 
greater improvement in traditional and inflammatory 
markers of CVD risk in clinical and non-clinical popula-
tions when compared with MICT.18 Although protocols 
differ, HIIT is characterised by short bursts of vigorous 
exercise (upwards of 80% maximal aerobic capacity) 
interspersed with periods of moderate intensity exercise 
or rest. In patients with CVD and heart transplant recipi-
ents, findings indicate that HIIT is well tolerated, safe and 
effective in improving CVD risk.19–21 Most recently, HIIT 
has been shown to be effective in improving physical func-
tion, inflammation and quality of life in peritoneal dialysis 
patients22; however, the effectiveness of HIIT versus MICT 
in RTRs has not yet, to our knowledge, been evaluated. 
With a lower time commitment and the aforementioned 
superior benefits, HIIT has the potential to provide a cred-
itable alternative to MICT. This type of exercise has also 
been perceived to be more enjoyable than MICT,23 a key 
component for changing and maintaining physical activity 
levels in RTRs identified through qualitative methods.24 
However, our patients’ views suggest that although HIIT 
may provide superior improvements of CVD risk factors 
with a shorter time commitment, the strenuous nature of 
the exercise might in itself present a barrier to participation 
in this population,24 and MICT such as brisk walking, may 
be more acceptable and encourage sustained participation.
Considering both the development of effective and 
sustainable exercise guidelines for lowering the CVD risk in 
RTRs and producing programmes with a wide appeal and 
good adherence, this pilot research aims to generate substan-
tial foundations towards understanding the feasibility and 
acceptability of differing aerobic exercise protocols in 
this unique population. The finding will contribute to the 
growing body of information not only in this population 
but in other chronic disease populations at risk of CVD and 
also determine the feasibility of proceeding to large and 
complex randomised control trials with primary outcomes 
focusing on the reduction of negative CVD outcomes.
objectives
Primary objective
To evaluate the feasibility of a trial protocol involving 
three different supervised aerobic exercise programmes 
in renal transplant recipients.
Secondary objectives
1. To assess participant experience and acceptability;
2. To explore potential for impact on physical func-
tion, body composition, habitual physical activity and 
non-invasive CVD risk factors;
3. To explore potential for impact on relevant blood, sa-
liva and urinary markers of metabolic health, systemic 
inflammatory status and immune function;
4. To assess the tolerability, practicality and patient per-
ceived usefulness of these assessments of cardiovascu-
lar disease risk;
5. To explore patient perception of their illness and 
symptoms, activity levels and quality of life.
MEthods And AnAlysIs
PAcE-Kd trial design
The PACE-KD trial is a randomised, three-arm paral-
lel-group study to determine the feasibility and accept-
ability of three different supervised aerobic exercise 
programmes. Figure 1 presents the study flow chart. There 
will be three parallel groups (exercise programmes): 
HIIT intervention A, HIIT intervention B and MICT 
(detailed below). Participants will be randomised to one 
of the three study arms and will complete 24 supervised 
sessions of the intervention (approximately three sessions 
per week over 8 weeks). After initial baseline testing, 
outcome measures will be attained at midtraining, imme-
diate post-training and 3 months post-training. Additional 
acute outcome measures will be taken during one exer-
cise session in the first 6 weeks and during one exercise 
session in the last 6 weeks of each exercise programme 
(see figure 2). Feasibility will be determined by assessing 
recruitment, compliance and completion. Acceptability 
and patient experience will be determined by a patient 
satisfaction questionnaire (PSQ) and an optional nested 
qualitative study (QPACE-KD) consisting of either one to 
one semistructured interviews or focus groups.
Patient involvement
The study was designed in consultation with patient 
partners. A patient involvement (PPI) group has been 
convened (lead by JS) and will meet regularly with the 
rest of the research team to review progress and address 
any issues that arise. The PPI partners will particularly 
take part in the qualitative analysis and interpretation and 
dissemination of the results.
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Figure 1 Study flowchart: overall study diagram. HIIT, high-intensity interval training; MICT, moderate-intensity continuous 
training; NICOM, Non-Invasive Cardiac Output Monitor; VO2, oxygen uptake.
Figure 2 Study flowchart: acute response sessions detailed diagram. NIRS, Near-Infrared Spectroscopy.
Participants and recruitment
A total of 24 participants with an established kidney 
transplant will be randomised (via computerised 
random number generator) to either HIIT interven-
tion A, HIIT intervention B or MICT (see table 1 for 
detailed inclusion and exclusion criteria). Patients will 
be screened by their own clinician for eligibility to enter 
the study. Eligible patients will be approached during 
their routine clinical appointments and will be provided 
with verbal and written study information. Addition-
ally, eligible patients who have given prior consent to 
be contacted regarding research opportunities will be 
contacted via the post. All patients will be given the 
opportunity to discuss the study in more detail and the 
opportunity to consider their participation (at least 
48 hours).
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Table 1 PACE-KD inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
 ► Diagnosed with chronic kidney disease and are a renal 
transplant recipient
 ►Male or female, aged 18 years or over
 ► Received renal transplant >12 weeks prior to entering the 
study
 ► Is willing and able to give informed consent for 
participation in the study
 ► Aged under 18 years
 ► Female participants who are pregnant, lactating or planning 
pregnancy during the course of the study
 ► Scheduled elective surgery or other procedures requiring 
general anaesthesia during the study
 ► Any other significant disease or disorder*
 ► Inability to give informed consent or comply with testing and 
training protocol for any reason
*That is, significant comorbidity including unstable hypertension, potentially lethal arrhythmia, myocardial infarction within 6 months, unstable 
angina, active liver disease, uncontrolled diabetes mellitus (HbA1c≥9%), advanced cerebral or peripheral vascular disease which, in the 
opinion of the patient’s own clinician, may either put the patient at risk because of participation in the study or may influence the result of the 
study or the patient’s ability to participate in the study.
Figure 3 Schematic diagram of HIIT regimens A and B. Each block shows stage duration in minutes. The final 5 min stage has 
been added to HIIT programme B to ensure the overall work done is matched for both protocols. HIIT, high-intensity interval 
training, VO2, oxygen uptake. 
Interventions
Each exercise programme will consist of 24 sessions over 
approximately 8 weeks. Participants will be allowed to drink 
plain water during exercise sessions. The programmes 
will be based on the three protocols described below.
HIIT programme A: (figure 3A)
Each session will consist of 16 min interval training with 
intervals of 4, 2 and 1 min duration at 80%, progressing 
to 90% oxygen uptake peak (VO2 peak) over the 8 weeks, 
separated by a 2 min active rest (~60% VO2 peak) giving a 
total exercise time of 30 min.
HIIT programme B: (figure 3B)
Each supervised session will consist of 4×4 min of interval 
training at 80% VO2 peak, progressing to 90% VO2 peak over 
the 8 weeks, separated by a 3 min active rest (~60% VO2 
peak) and with a final 5 min recovery stage to ensure that 
overall work done is matched for both HIIT protocols, 
therefore also giving a total exercise time of 30 min.
MICT exercise intervention
Each supervised session will consist of continuous brisk 
cycling for ~40 min with a target rating of perceived exer-
tion (RPE)of 12–14 (somewhat hard). This is equivalent 
to 50%–60% VO2 peak and will be matched to the HIIT 
protocols for total external work done based on calcu-
lations of percentage of peak watts obtained from the 
VO2 peak test. In this way, for each individual the overall 
energy expenditure during the session would be the same 
regardless of the trial they are assigned to.
All exercise sessions will be preceded by a 5 min low 
intensity warm up and followed by a 10 min cool down.
study procedures
The study outcomes, measurement methods and assess-
ment time periods are summarised in table 2, and a 
detailed overview of each measurement is provided at 
the end of this section. Data on recruitment, numbers of 
sessions attended and completed in accordance with the 
protocol and dropout will be recorded and continuously 
monitored.
Baseline visit (visit 1)
At visit 1, informed consent will be obtained on arrival. 
Participants will perform a standard maximal exercise 
test (VO2 peak test) in the presence of a cardiac nurse. This 
test will be preceded by a 12-lead ECG and subject to the 
confirmed absence of any contraindications.
Measurements of cardiac function, physical function, 
anthropometry, body composition and blood, urine 
and saliva samples will be collected. A survey pack will 
be completed and an accelerometer given to measure 
habitual physical activity over approximately 7 days.
Training visits
Participants will attend 24 supervised exercise sessions 
(approximately three per week for 8 weeks) of either: HIIT 
A, HIIT B or MICT (as outlined above). At the beginning 
of each session, participants will be asked to complete 
an internally designed illness–symptom questionnaire. 
They will also be provided with a copy to complete over 
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the weekend between sessions. The questionnaire will 
provide data on illness symptoms particularly relating to 
upper respiratory, digestive and urinary tract.
Acute response sessions
At one of the first six and at one of the final six exer-
cise sessions, a resting blood sample will be collected 
immediately prior to the usual training session, immedi-
ately post-training session, 1 hour post-training session, 
4 hour post-training session and immediately prior to 
the start of the next training session. Saliva samples will 
be taken in conjunction with each blood sample. Partic-
ipants will be asked to abstain from caffeine and alcohol 
for 24 hours prior to these two acute testing sessions, and 
on acute testing session 2 asked to consume a similar 
diet to the 24 hours prior to acute session 1. During the 
training session, a muscle O2 saturation monitor will be 
attached to the calf muscle (non-invasively) and will be 
removed following the 4hour blood sample. Following 
the 1 hour samples, prior to the 4 hour sample, patients 
will be provided with light refreshments. They will be 
asked to refrain from consuming alcohol and caffeine 
and from partaking in strenuous exercise.
Midtraining visit
The midtraining visit will take place between weeks 3 
and 5. At this visit, the experimental tests described in 
the baseline visit will be repeated with the exception of 
the VO2 peak test and the accelerometer for habitual phys-
ical activity. The survey pack as described in the base-
line visit will be administered, completed and collected 
during this visit.
Immediate post-training visit
The immediate post-training visit will take place within 
14 days of the final exercise session taking place. All 
experimental tests and the survey pack outlined in 
the baseline visit will be repeated. An accelerometer 
will be fitted as in the baseline visit and returned after 
1 week.
Three month post-training visit
The three month post-training visit will take place approx-
imately three months following the final exercise session. 
The visit will be very similar to the midtraining visit. All 
experimental tests and the survey pack outlined in the 
aforementioned visit will be repeated with the exclusion 
of the VO2 peak test. There will be no more experimental 
measures after this visit.
An internally designed patient satisfaction question-
naire (PSQ) will be administered once at the end of study 
participation. The PSQ is designed to assess the accept-
ability of the study and experiences of the patients in each 
of the trial groups with particular focus on tolerability, 
practicality, enjoyment and perceived usefulness of the 
study measures and of the study as a whole. Participants 
who cease involvement in the study prior the final assess-
ments will also be invited to complete the questionnaire. 
This will be optional.
study outcome measures
VO2 peak test
Standard ramp protocol; increasing workload of approx-
imately 1 W every 4 s (10–15 w/min) ensuring volitional 
exhaustion within 12–15 min25 on a stationary electronically 
braked cycle ergometer (Lode Excalibur Sport, Groningen, 
Netherlands). Participants will be encouraged to cycle at a 
continuous cadence (~70 rpm). The highest oxygen uptake 
will be measured in this study (VO2 peak) as true maximal 
VO2 (VO2 max) is less commonly achieved in deconditioned 
and/or clinical patients. Results of this test will be used to 
determine training workloads.
Clinical information
Clinical information will be extracted from the medical 
notes including: age, gender, ethnicity, primary cause of 
renal failure, transplant type, time since transplant, dialysis 
duration, comorbidities, blood/urine results, current medi-
cation and smoking habits. This information will be used 
to primarily account for cofounding variables and analyses 
of differences and similarities between intervention arm 
groups.
Anthropometric measures
Anthropometric measures of height, weight and waist 
and hip circumference will be attained in accordance 
with standard protocols.26
Body composition
Bioelectrical impedance analysis performed on an InBody 
analyser (InBody 370, Chicago, Illinois, USA) will be used 
to estimate body composition (eg, body fat percentage and 
fat-free mass). This is a painless, non-invasive method27 28 
previously validated for use in patients with CKD .29
Cardiovascular condition and function
A non-invasive cardiac output monitor (Cheetah Medical, 
Maidenhead, UK) will be used to assess heart function 
using cardiac bioreactance analysis. This method is safe, 
quick and validated30 for assessing haemodynamic param-
eters including cardiac output (heart rate x stroke volume) 
and total peripheral resistance.
Pulse wave analysis
Pulse wave analysis will be measured non-invasively to 
determine arterial stiffness using applanation tonometry 
methods (Sphygmocor, AtCor Medical, West Ryde, New 
South Wales, Australia). Arterial pressure waveforms are 
recorded superficially at the radial artery by an experi-
enced laboratory technician by applanating the artery with 
a high-fidelity hand-held tonometer at the site of maximal 
pulsation. Consistent and reproducible waveforms are 
recorded for 20 s. This is a safe procedure and a measure 
of this type has been performed in patients with CKD previ-
ously.13 14
Physical function
Physical function will be assessed using three tests. The 
sit-to-stand (STS) test will be used to ascertain functional 
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ability and has been widely used in the CKD popula-
tion.31–33 Participants will be asked to sit on a hard upright 
chair with their feet flat on the floor and knees bent at 
90°. One cycle is considered complete when the partici-
pant stands up and sits down again to the starting position 
(without using their hands). There are two tests within 
the STS:
 ► STS5: The time taken for patients to stand up from 
a seated position and sit back down again five times. 
 ► STS60: The number of STS cycles achieved in 60 s and 
is a surrogate measure of muscular endurance.
The 4 m walk test will be used to assess gait speed. 
Participants will be asked to walk 4 m at their usual pace 
for one practice and two timed trials. The better score (in 
seconds) on the timed trials will be recorded.
Isometric plantar flexion strength (gastrocnemius and 
soleus strength) will be assessed using a modified Wii Fit 
board (Nintendo, Kyoto, Japan). Participants will sit with 
their legs bent to 90° with their feet flat on the board. A 
strap will be placed around the board and over the knees. 
Participants will then be asked to raise their heels off the 
board causing a downward force to be exerted on the board.
Muscle oxygen saturation
Prior to the acute testing sessions a small non-invasive 
muscle O2 saturation device (BSXInsight, BSXAthletics, 
Texas, USA) will be placed onto the calf muscle and secured 
with a small bandage. The device will be removed following 
the 4hour sample collection. This will measure muscle O2 
saturation using NIRS and has been used in a variety of 
diseases previously.34 
Saliva sampling and storage
Saliva samples will be collected into sterile plastic 
containers. Participants will swallow to empty the mouth, 
then open and hold the container themselves before 
performing a passive dribble of saliva collected under the 
tongue over the next 2 min. Following centrifugation, the 
supernatant will be aliquoted and frozen for future anal-
ysis, primarily for secretory immunoglobulin A to investi-
gate mucosal immunity.
Urine sampling and storage
A urine sample will be requested during the baseline visit. 
This sample will be analysed for urinary protein excre-
tion, bacteriuria and urinary tract infection susceptibility.
Venous blood sampling and analysis
Venous blood will be collected using venepuncture of 
the antecubital vein and prepared appropriately for the 
following analysis:
 ► A cytometric bead array technique will be used to 
allow bulk analysis of a panel of proinflammatory 
and anti-inflammatory cytokines, including but not 
limited to interleukin (IL)-1, IL-2, IL-6, IL-10, tumour 
necrosis factor-alpha and interferon gamma.
 ► Other markers of inflammation, C-reactive 
protein (CRP) and oxidative stress, malondialdehyde 
(MDA) will be assessed by ELISA.
 ► Phenotyping of microparticles using flow cytometry.
 ► Immune cell subsets using flow cytometry.
 ► Full blood count and renal profile analysis, which 
includes estimated glomerular filtration rate, urea, 
bicarbonate, creatinine, sodium, potassium and phos-
phate measures.
Questionnaires
Participants will be asked to complete a survey pack 
containing the following: (1) Renal Patient Outcome 
Scale; a validated questionnaire that measures the 
presence and severity of disease related symptoms with 
the addition of a transplant specific question set.35 (2) 
Fatigue Scale; an internally designed Likert scale on 
feelings of tiredness. (3) EuroQol; a short widely used 
quality of life questionnaire.36 (4) Illness Perception 
Questionnaire—Revised; an 84-item questionnaire 
which is used to assess the principle components of 
illness representations.37 This questionnaire has been 
tailored for patients with chronic kidney disease and will 
assess their perceptions of physical activity as treatment. 
(5) Duke Activity Status Index; a 12-item questionnaire 
that uses self-reported physical work capacity to esti-
mate peak metabolic equivalents and has been shown 
to be a valid measurement of functional capacity.38 
(6) Brief Pain Inventory—Short Form; a nine-item 
self-administered questionnaire used to evaluate the 
severity of a patient's pain and the impact of this pain 
on the patient's daily functioning.39 (7) The Pittsburgh 
Sleep Quality Index; a self-report questionnaire that 
assesses sleep quality over a onemonth time interval40 
(8) Epworth Sleepiness Scale (ESS); the ESS measures 
a person’s general level of daytime sleepiness or their 
average sleep propensity in daily life.41
Accelerometry
An ActiGraph wGT3X-BT accelerometer (Actigraph, 
Pensacola, Florida, USA) will be provided to wear on the 
waist which will record habitual physical activity (returned 
after 1 week).
nested qualitative study (QPAcE-Kd)
Six participants from each intervention arm will be invited 
to an audiorecorded focus group or semistructured inter-
view to discuss their experiences of the study and the 
intervention in more detail and to gather suggestions 
for relevant and acceptable design of future randomised 
controlled trials. The qualitative phase will be conducted 
by a practised researcher uninvolved with the aforemen-
tioned study protocol to encourage freedom of expres-
sion. Both one-to-one semistructured interviews and focus 
groups will be used to provide different but complemen-
tary qualitative information. The interviews will ascertain 
individual perspectives and feelings about the interven-
tion and outcome protocol in the light of personal and 
individual experiences of having completed the feasibility 
study. On the other hand, focus groups will elicit percep-
tions which are particularly useful when there is some 
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consensus and meaning about the existence of a commu-
nity or shared voice.
The QPACE-KD study is an optional addition to PACE-
KD. The QPACE-KD protocol will be explained to the 
patient, and they will be given ample opportunity to ask 
questions and at least 48 hours to decide whether or not 
to participate. If they agree, separate QPACE-KD written 
informed consent will be attained before the interview 
or focus group takes place. During the interviews and 
focus groups, the facilitator will introduce the process, 
explaining the background and reasons for the study, how 
the interview will proceed and details of audio recording 
and note taking. Participants will be reassured about the 
preservation of their anonymity and confidentiality as 
well as given the opportunity to ask questions.
Transcripts will only include non-identifying informa-
tion. Individual’s names and personal details will not 
be included in the completed transcripts. Similarly, any 
written notes taken during the interviews will not include 
any identifiable personal data.
data collection and management
Data at all time points will be collected in case report 
forms by the trial team. All data will be entered into a 
secure database and will only be accessible on pass-
word-protected computers at University Hospitals of 
Leicester NHS Trust (UHL), University of Leicester and 
Loughborough University by relevant members of the 
study team. No identifying information will be kept in 
electronic form. All source data and original participant 
identities will be kept in a locked office in the trial site file 
only at UHL.
sample size
As the trial has a primary outcome of feasibility the 
study sample size is pragmatic and a power calculation is 
neither relevant nor possible. Data collected on secondary 
outcome measures will provide data on which sample size 
calculations can be performed in future well-informed 
randomised controlled trials. We have chosen specific 
and relevant secondary outcome variables that may be 
suitable future primary outcomes.
data analysis
The primary outcome will assess the feasibility of study 
components such as recruitment, randomisation, reten-
tion, assessment procedures and the implementation of 
the interventions. These will be quantified by analysing 
factors such as but not limited to: numbers screened, 
numbers enrolled, proportion of eligible patients 
enrolled, intervention-specific retention rates, rates of 
adherence to protocol per intervention and proportion 
of training sessions and assessment sessions completed. 
The criteria for determining study and intervention feasi-
bility will be as follows: Compliance: attending >70% of 
sessions and retention/completion:>80% of participants.
Due to the small sample size, complex statistical anal-
ysis will not be performed on the secondary outcomes; 
however, we will use simple analysis (eg, t-test, linear regres-
sion) to investigate statistical differences for exploratory 
information only.
Interview data will be analysed according to the princi-
ples of interpretive thematic analysis using a framework 
approach42 to explore themes emerging from patient 
journeys through and experiences of the interventions 
and outcome measures. The whole research team, 
including patient partners, will be involved in qualitative 
analysis to avoid individual bias.
EthIcs And dIssEMInAtIon
Ethical issues
The University Hospitals of Leicester NHS Trust agreed 
to act as sponsor for this study on 31 October 2016 
(EDGE 88714). The protocol was reviewed by the East 
Midlands-Nottingham Research Ethics Committee 
(REC) and was given a favourable opinion (REC ref 16/
EM/0482) on 04 January 2017. Health Research Authority 
regulatory approval was given on 27 January 2017, and 
the study was adopted on the NIHR portfolio on 12 
January 2017. Local governance approval was granted by 
UHL Research and Innovation on 02 March 2017. Steps 
have been taken when designing this protocol to mini-
mise the ethical implications and ensure patient welfare. 
The study will comply with the International Conference 
for Harmonisation of Good Clinical Practice guidelines 
and the Research Governance Framework for Health and 
Social Care.
dissemination plan and impact
On completion, the results of this study will be published 
in peer-reviewed journals and presented at national and 
international conferences. Participant level data will be 
available following publication of results on request. 
Results will also be disseminated to the patient and public 
community via social media and newsletter articles and 
presentations at patient conferences and forums, lead by 
the patient partners.
It is anticipated that the results of this study will inform 
future design of larger randomised controlled trials in 
this subject area and contribute to future specific physical 
activity guidelines in this population.
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